Literature DB >> 27993802

Atypical autoimmune adverse effects with checkpoint blockade therapies.

C F Friedman1,2, A Snyder1,2.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 27993802     DOI: 10.1093/annonc/mdw658

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

Review 1.  Checkpoint Inhibitors, Palliative Care, or Hospice.

Authors:  Mellar P Davis; Rajiv Panikkar
Journal:  Curr Oncol Rep       Date:  2018-01-19       Impact factor: 5.075

Review 2.  Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Authors:  Christiane Thallinger; Thorsten Füreder; Matthias Preusser; Gerwin Heller; Leonhard Müllauer; Christoph Höller; Helmut Prosch; Natalija Frank; Rafal Swierzewski; Walter Berger; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2017-11-02       Impact factor: 1.704

Review 3.  Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.

Authors:  Yungang Wang; Shouyan Deng; Jie Xu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

4.  PD-L1 in the palm of your hand: palmitoylation as a target for immuno-oncology.

Authors:  Andreas von Knethen; Bernhard Brüne
Journal:  Signal Transduct Target Ther       Date:  2019-06-07

5.  Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.

Authors:  Yuan Liu; Zhi Liu; Xuejun Zeng; Chunmei Bai; Lin Chen; Songbai Lin; Xinlun Tian
Journal:  BMC Cancer       Date:  2019-12-05       Impact factor: 4.430

6.  Chlorin e6-Conjugated and PEGylated Immune Checkpoint Inhibitor Nanocomposites for Pulmonary Metastatic Colorectal Cancer.

Authors:  Young-Il Jeong; So Young Yoo; Jeong Heo; Dae Hwan Kang
Journal:  ACS Omega       Date:  2019-11-01

Review 7.  Updated Understanding of Cancer as a Metabolic and Telomere-Driven Disease, and Proposal for Complex Personalized Treatment, a Hypothesis.

Authors:  Cristian Muresanu; Siva G Somasundaram; Sergey V Vissarionov; Luis Fernando Torres Solis; Arturo Solís Herrera; Cecil E Kirkland; Gjumrakch Aliev
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

8.  Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma.

Authors:  Nada Chaoul; Serena Mancarella; Luigi Lupo; Gianluigi Giannelli; Francesco Dituri
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.